54% and a negative trailing twelve-month return on equity of 1,116. Further. 11, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. com uses cookies on this site. Cookies are used to offer you a better browsing experience and to analyze our traffic. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies (TSX: TH) is a specialty pharmaceutical company addressing unmet medical needs by bringing to market specialized therapies for people with orphan medical conditions, including. By continuing to use our service, you agree to our use of cookies. By continuing to use our service, you agree to our use of cookies. Theratechnologies is leveraging its SORT1+ Technology™ to develop a new class of therapy that targets sortilin (SORT1)-positive cancers by linking anticancer drugs to proprietary peptides that specifically bind to the sortilin receptor. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development. 03, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. This news release constitutes a "designated news release" for the purposes of. These companies provide a lot of detail to the OTC Markets Group including audited financials. This work is well underway and will be considered by the SAC as part of their meeting, which is scheduled for the latter half of March when the analyses are expected to be ready. 36 morning pop. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650 [email protected] is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. Theratechnologies is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. If you have HIV, it's important to know the difference. com. Theratechnologies Inc. 82 million. Stockhouse. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Theratechnologies. Stockhouse. Small cap stock market news and analysis, portfolio tracking, investor message boards and forums (bullboards), newsletter aggregation and detailed snapshots of stock quotes for. (“Theratechnologies”, the “Company”, or “we”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has completed the previously announced consolidation of the issued. 31, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. com. Amount of cash a business has after it has met its financial obligations such as debt and outstanding payments. com uses cookies on this site. Early Warning Report Issued Pursuant to National Instrument 62-103 - Acquisition of Securities of Theratechnologies Inc. Shares of Theratechnologies are up 4. (2022-05-31 | TSX:TH) Theratechnologies Announces New Head of Investor Relations. . Cookies are used to. Theratechnologies reduces R&D head count to compensate for sales setback. (2022-02-24 | TSX:TH) Theratechnologies Reports Financial Results for Fiscal 2021 and Provides Business Update. 18% on the last trading day (Wednesday, 25th Oct 2023), rising from $1. 7 ( 1D) About THTX In 2022, THTX's revenue was 80. Company Description: Theratechnologies is pepped up on peptides. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a commercial-stage biopharmaceutical company addressing unmet medical needs by bringing to market specialized therapies for people with orphan medical. Wainwright NASH Investor Conference. com. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Data presented at AMCP Nexus 2023. Further information about Theratechnologies is available on the Company's website at , on SEDAR at and on. com uses cookies on this site. Theratechnologies Inc. ("Theratechnologies" or the "Company"). com uses cookies on this site. com uses cookies on this site. Cookies are used to offer you a better browsing experience and to. TO) stock quote, history, news and other vital information to help you with your stock trading and investing. GUD | Complete Knight Therapeutics Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies announced today that it will report its financial results for the second quarter of fiscal 2021 ended May 31, 2021 on. (2021-05-31 | TSX:TH) Theratechnologies Hires Vice President, Human Resources. Theratechnologies Reports Financial Results and Business Updates for the Fourth Quarter and Full Year Fiscal 2022. S. Stockhouse. 19, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. – Form 40-F for Fiscal Year Ended November 30, 2011 – Your File No. 63. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Philippe Dubuc Senior Vice President and Chief Financial Officer Phone: +1-438-315-6608 [email protected] uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Shares of Theratechnologies are up 4. Biopharma Theratechnologies (NASDAQ:THTX) Friday announced that a study evaluating an intramuscular (IM) method of administration for its therapy, Trogarzo, did not meet the primary endpoint. com. 00%. Stockhouse. MONTREAL, Nov. TORONTO, May 19, 2023. By continuing to use our service, you agree to our use of cookies. About Theratechnologies Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of. Senior Director, Investor Relations. Betteryear2. (THTX) Stock Price, Quote, latest community messages, chart, news and other stock related information. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced dosing of the first participant in Part 3 of its Phase 1 clinical trial of. MONTREAL, Oct. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic. W. Theratechnologies Stock (NASDAQ: THTX) stock price, news, charts, stock research, profile. 10% least volatile stocks in CA Market. com uses cookies on this site. Investor Relations. 51 to 200 Employees. The firm offers its product under the brand name of EGRIFTA, which is an approved therapy for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. We also use them to share usage. OTCQX – this is the premium tier of OTC stocks. Find the latest Theratechnologies Inc. GlobeNewswire. Cookies are used to offer you a better browsing experience and to analyze our traffic. TH | May 19, 2023. MONTREAL, Aug. (TSX: EXRO) (OTCQB: EXROF) (the "Company" or "Exro" ), a leading clean technology company which has developed a new class of power electronics for electric motors and powertrains, announced today its financial results for the three months ended March 31, 2022. communications@theratech. 10% most volatile stocks in CA Market. MONTREAL, Jan. TH | July 20, 2023. Cookies are used to offer you a better browsing experience and to analyze our traffic. (TSX: TH) announced today that the Supreme Court of Canada has granted its appeal and dismissed 121851 Canada Inc. stockhouse. 11/05/2020 4:15:02 PM. com uses cookies on this site. Theratechnologies Inc. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. By continuing to use our service, you agree to our use of cookies. 1M. By continuing to use our service, you agree to our use of cookies. 28, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (2020-03-31 | tsx:th) theratechnologies provides business update related to current covid-19 situation Stockhouse. 31K. 26 +15. (TSE:TH) posted its quarterly earnings data on Tuesday, September, 26th. (2013-04-03 | TSX:TH) Theratechnologies Inc. MONTREAL, June 22, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 04) earnings per share (EPS) for the quarter. TH | May 19, 2023. With the company starting 2023 with 8,725 employees, that’s an 11. 25. Theratechnologies Inc. Theratechnologies Inc (Theratechnologies) is a biopharmaceutical company that focuses on the discovery and development of drugs for people with orphan medical conditions. VANCOUVER, British Columbia, Nov. Heures de négociation. $30. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced today that it will report financial results for its second quarter of fiscal 2022 ended May 31 on Thursday, July 14, 2022. home message. com uses cookies on this site. ("Theratechnologies" or the "Company") (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has established an at-the-market ("ATM") equity program allowing Theratechnologies to. com uses cookies on this site. 2% for this period. MONTREAL, April 14, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. We also use them to share. -4. 4. Microsoft to invest $500M in Quebec AI economy. (2021-12-06 | TSX:TH) Theratechnologies Submits Supplemental Biologics License Application to FDA Advancing Development of IV Push Trogarzo® for Patients Living With HIV. View real-time stock prices and stock quotes for a full financial overview. com. 0. (TH. By continuing to use our service, you agree to our use of cookies. 28 $1. MONTREAL, Aug. 4%. Cookies are used to offer you a better browsing experience and to analyze our traffic. (Translation of registrant’s name into English) 2310 Alfred-Nobel Boulevard . 2. MONTREAL, June 22, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Second quarter 2022 earnings: Revenues miss analyst expectations Jul 15. Theratechnologies Announces Fiscal Year 2023 Guidance and Operating Plan’s Key Objectives. Type: Company - Public (TH) Revenue: $5 to $25 million (USD) Biotech & Pharmaceuticals. Q3 2023 consolidated revenue of $20. S. T. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Investor Relations. Losses were -47. A high-level overview of Theratechnologies Inc. Stockhouse. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650 [email protected] Inc. About Theratechnologies Theratechnologies (Nasdaq: THTX) (TSX: TH) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. has received a $100 million binding commitment with respect to a non-dilutive term loan with an affiliate of Marathon Asset Management. communications@theratech. US Headquarters. 2015 Peel Street, 11th Floor Montréal, Québec Canada H3A 1T8 Phone: 514 336-7800 Fax: 514 331-9691. This suggests a possible upside of 2,471. 14, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies Stock Price, News and Company Updates. Theratechnologies (TH) and partners contributed $2 million for a research project for a new treatment for metastatic cancer. 1. 75%. T. Theratechnologies . ET. We also use them to share. Theratechnologies had a negative net margin of 36. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. MONTREAL, Oct. com uses cookies on this site. . Who is Theratechnologies. This module allows you to check different measures of market premium (i. We also use them to share usage information with our partners. Theratechnologies is pepped up on peptides. TH | February 28, 2023. 17. See a list of the most recent Stock Forum posts on Stockhouse. MONTREAL, July 31, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (2021-06-30 | TSX:TH) CORRECTION: Theratechnologies to Announce Financial Results for Its Second Quarter Fiscal 2021. 9 million as at August 31, 2023. . Stockhouse. Marsolais’ presentation will be available through. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced receipt of the 2023 Industrial Research Sectoral Group (RSRI) Innovation Award from the CQDM (for. Thank you. (TH. Theratechnologies Inc. Image source: The Motley Fool. 86 million for the quarter. com uses cookies on this site. 72%. com uses cookies on this site. The company's proprietary technologies include Long Acting Peptides, a peptide stabilization technology that. US Headquarters. Cookies are used to offer you a better browsing experience and to analyze our traffic. Data Link's cloud-based technology platform allows you to search, discover and access data and analytics for seamless integration via cloud APIs. 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (NASDAQ:THTX) Q3 2021 Earnings Call October 13, 2021 8:30 A. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. US Headquarters. (TH) has had its first patient receive a dose of TH1902, for the treatment of sortilin positive (SORT1+) solid tumours. 20% from a day low at $1. NCU. We also use them to share usage. We also use them to share usage information with our partners. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a. FY2022 revenue. (2021-03-20 | TSX:TH) Theratechnologies Announces New Data Demonstrating Tesamorelin's Positive Effect on Immune Response Linked to Liver Inflammation. Stockhouse. m. The Canadian company develops peptide sequences to treat endocrine and metabolic conditions such as growth hormone deficiencies. . 22, 2023 (GLOBE NEWSWIRE) -- B2Gold Corp. Cookies are used to offer you a better browsing experience and to analyze our traffic. Philippe Dubuc Senior Vice President and Chief Financial Officer Phone: +1-438-315-6608 ir@theratech. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. By continuing to use our service, you agree to our use of cookies. MONTREAL, Feb. Investor inquiries: Elif McDonald. Theratechnologies Announces First Patient Dosed in Phase 1 Clinical Trial of TH1902 for Sortilin Positive Solid Tumors Stockhouse. By continuing to use our service, you agree to our use of cookies. Stockhouse. By continuing to use our service, you agree to our use of cookies. 9 million as at August 31, 2023. 9%, while the Biotechs industry saw earnings growing at 17. By continuing to use our service, you agree to our use of cookies. La Bourse de Toronto a clôturé en hausse mardi pour une troisième séance consécutive, tandis que les grands indices boursiers américains ont avancé eux aussi. 8 million. (2021-11-03 | TSX:TH) Theratechnologies to Present at the Credit Suisse 30th Annual Healthcare Conference on November 11, 2021. 89 $2. Cookies are used to offer you a better browsing experience and to analyze our traffic. Theratechnologies Inc. $44. MONTREAL, Feb. 4. . THERATECHNOLOGIES INC. com. Theratechnologies Unveils New Positive Data for Its Investigational Peptide-Drug Conjugates Targeting Sortilin Positive Cancers. Stockhouse. Theratechnologies Inc. 2022 Revenue Guidance Theratechnologies anticipates fiscal 2022 revenue to be in the range of $79 million and $84 million for full fiscal 2022, or growth of the commercial portfolio to be in the. TH Stock Message Board for Investors. . Last Reviewed: February 24, 2023. 31, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 49) by $0. MONTREAL, Feb. Northwest also announces an update on its. Theratechnologies is currently developing a platform of proprietary peptides called SORT1+ Technology TM for cancer drug development targeting SORT1. Montreal-based biopharmaceutical company Theratechnologies Inc. H. Stockhouse. Theratechnologies Inc. 24, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. com uses cookies on this site. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. , a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced further changes to its operations that will see a tapering. 24, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Headquartered in Montreal, Theratechnologies is a biotech company that develops innovative therapies for unmet medical needs in HIV, oncology, and NASH, a type of liver disease. (2019-08-12 | TSX:TH) Theratechnologies Files Application to List on NASDAQ. Marsolais will present at the H. MONTREAL, July 07, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 74M. Stable Share Price: TH is more volatile than 90% of Canadian stocks over the past 3 months, typically moving +/- 25% a week. MONTREAL, Feb. It’s lead investigational peptide drug conjugate linked to docetaxel, a well-established and well-characterized cytotoxic agent used in the. 38. stock news by MarketWatch. Statut du système de négociation. Stockhouse. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650 [email protected] (TH) has posted net revenue estimates for fourth quarter and the full fiscal year ending Nov 30, 2020. These pharmaceuticals. We currently market prescription products for people with HIV in the United States. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650For the three- and six-month periods ended May 31, 2023, consolidated revenue was $17,549,000 and $37,457,000, compared to $19,268,000 and $37,825,000 for the same periods ended May 31, 2022. Fri, 17 Apr 2015 15:08:33 GMT ~ Supreme Court of Canada rules in favour of Theratechnologies. Theratechnologies inc. is an employee of TaiMed Biologics USA, Inc. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has closed its previously announced public offering (the “Public. MONTREAL, April 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Business Update. Gary Littlejohn. D. About SORT1+ Technology™ and TH1902. The company’s marketed products include Egrifta SV is indicated to reduce excess abdominal fat in human immunodeficiency virus (HIV. NCU. Theratechnologies’ R&D staff is bearing the brunt of. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX) ), a biopharmaceutical company focused on the development. H4S 2B4 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F x Form 40-F ¨Theratechnologies has established its SORT1+ Technology™ platform as an engine for the development of proprietary peptide-drug conjugates (PDCs) that target the sortilin (SORT1) receptor, which is expressed in multiple tumor types. We currently market prescription products for people with. MONTREAL, Nov. 23 to a day high of $1. US Headquarters. com. Stockhouse. Investor inquiries: Elif McDonald. Whether TH1902 impacts the chemoresistance phenotype of human triple-negative breast CSC. Join the discussion: Find out what everybody’s saying about this stock on the Theratechnologies Bullboard, and check out the rest of Stockhouse’s stock forums and message boards. Common Shares (THTX) Stock Price, Quote, News & History | Nasdaq Nasdaq Data Link's products page Investors may trade in the Pre-Market (4:00. On average, they expect the company's stock price to reach $36. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 26, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Consensus forecasts updated Jul 21. B2Gold Declares Fourth Quarter 2023 Dividend. : Nasdaq Theratechnologies Inc. Montréal, Québec, Canada . Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (“Theratechnologies”), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its fourth quarter and full year fiscal 2022 ended November 30,. Theratechnologies Announces Certain Preliminary Q3 2023 Financial Highlights. View real-time stock prices and stock quotes for a full financial overview. E-Poster website launch date and time: Saturday, April 10, 2021, 8:30 AM. TH | February 28, 2023. com uses cookies on this site. Montréal, Québec, Canada . Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. It is the Company’s proprietary. Ibalizumab-uiyk (Trogarzo) is a medical infusion treatment for HIV infection in adults for whom other HIV medicines have not worked. 16%. 51 S1. , a biopharmaceutical company, engages in the discovery of therapeutic products for commercialization. com uses cookies on this site. High expression of the sortilin (SORT1) receptor correlates with decreased survival in triple‐negative breast cancer (TNBC) patients. 67% from the latest price. 22, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. com uses cookies on this site. MONTREAL, March 29, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Stockhouse. Stockhouse. FAQ – Émetteurs inscrits NOUVEAU. Theratechnologies Appoints New Board Member. By continuing to use our service, you agree to our use of cookies. Visit the TSX ETF Investor Centre to access our screener and comparison tool. Amendment Withdraws the Condition to File HFS Report to the FDA to Access the US$20 Million Second Tranche. 250 Howe Street, Suite 1400 Vancouver, British Columbia, V6C 3S7 Click to expand. , a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. Theratechnologies’ CFO to Attend Cantor Global Healthcare Conference in New York City. lgibson. Real-time discussion about Theratechnologies Inc. The webinar will also address system-level barriers and present real-world. Vice President, Communications and Corporate Affairs. Cookies are used to offer you a better browsing experience and to analyze our traffic. 08). Clinical-stage pharmaceutical company Theralase Technologies Inc. The company’s previously announced offering was conducted by a syndicate of underwriters, including companies such as Canaccord Genuity. By continuing to use our service, you agree to our use of cookies. This news release constitutes a “designated news release” for the purposes of the Company’s. 69, 1. Biopharmaceutical company Theratechnologies Inc. Stockhouse. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs.